The important role of IL-33 in AD is further evidenced by a phase 2a clinical trial, demonstrating that Etokimab, an anti-IL-33 monoclonal IgG1 antibody, exhibited a therapeutic benefit for AD [13]. The gene discussed is IL33; the disease is Alzheimer disease.